MedTrace Logo

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

NCT05265650 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-19

No results posted yet for this study

Summary

This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.

Conditions

  • Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG

BO-112 in combination with ablative radiotherapy (SABR) and nivolumab

Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.

PROCEDURE

Tissue Biopsies

Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.

Sponsors & Collaborators

  • Highlight Therapeutics

    collaborator INDUSTRY

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Maria E Rodriguez, PhD · Clinica Universidad de Navarra

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2024-03-31
Completion
2024-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265650 on ClinicalTrials.gov